Motion sickness in childhood migraine: the efficacy and safety of Griffonia simplicifolia/Magnesium complex

"\"Introduction The purpose of this study was to assess the efficacy and safety. of Griffonia simplicifolia\\\/Magnesium complex in a paediatric sample with. motion sickness (MS), a very frequent migraine equivalent in childhood.. Methods The study population consisted of 254 children (mean age:. 7.56±1.49 years; 141 males and 113 females) with motion sickness, recruited from the Headache Centre for Developmental Age, Child and Adolescent. Neuropsychiatry Clinic, Second University of Naples.. Griffonia\\\/Magnesium complex (50 mg and 200 mg, respectively) was orally. administered as prophylactic therapy for MS twice a day for 3 months to one. group (Group A; 127 children; mean age: 7.69±2.32; 72 males) and no therapy. for MS was administered to the second group (Group B; 127 children;. mean age: 8.02±1.98; 69 males). The signs of motion sickness were identified. with an ad hoc questionnaire that was administered to all subjects and parents. of both groups.. In order to verify the efficacy on MS of the Griffonia\\\/Magnesium complex. treatment, we compared the MS prevalence after 3 months of treatment in. Group A with MS prevalence after 3 months of observation in Group B. (without MS prophylactic treatment).. Results After 3 months (T1) Group A showed a MS prevalence of 36%, significantly. lower than MS prevalence in Group B (73%) (p<0.001). No relevant. side effects were reported.. Discussion and conclusions The role of Griffonia\\\/Magnesium complex as a. potential treatment with mid-term efficacy also for recurrent periodic syndrome. as motion sickness.\""